cladribine has been researched along with sphingosine in 28 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 6 (21.43) | 29.6817 |
| 2010's | 22 (78.57) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Burton, JM; O'Connor, P | 1 |
| Gonsette, RE | 1 |
| Borriello, G; Cefaro, LA; Gasperini, C; Pozzilli, C; Prosperini, L; Tosto, G | 1 |
| Hartung, HP; Kieseier, BC; Stüve, O; Wiendl, H | 1 |
| Gasperini, C; Ruggieri, S | 1 |
| Zéphir, H | 1 |
| Carroll, WM | 1 |
| Link, H; Martin, R | 1 |
| Havla, J; Hohlfeld, R; Kümpfel, T | 1 |
| Hecht, B | 1 |
| Mann, H | 1 |
| Marriott, JJ; O'Connor, PW | 1 |
| Nau, JY | 1 |
| Banwell, B; Yiu, EM | 1 |
| Hartung, HP; Kieseier, BC; Stüve, O; Warnke, C; Wiendl, H | 1 |
| Fontoura, P; Garren, H | 1 |
| Fox, EJ | 1 |
| Gold, R | 1 |
| Bonzano, L; De Stefano, N; Roccatagliata, L; Sormani, MP | 1 |
| Jadidi-Niaragh, F; Mirshafiey, A | 1 |
| Filippi, M | 1 |
| Carmona, O; Cocco, E; Drulovic, J; Duddy, M; Eggers, C; Gold, R; Haghikia, A; Zéphir, H | 1 |
| Csépány, T | 1 |
| Hohlfeld, R | 1 |
| Killestein, J; Polman, CH; Rudick, RA | 1 |
| Graham-Rowe, D | 1 |
| Ais-Larisgoitia, A; de Lorenzo-Pinto, A; Rodríguez-González, CG | 1 |
| Bandichhor, R; Iqbal, J; Mulakayala, N; Oruganti, S; Rao, P | 1 |
18 review(s) available for cladribine and sphingosine
| Article | Year |
|---|---|
Novel oral agents for multiple sclerosis.
Topics: Administration, Oral; Anti-Bacterial Agents; Anti-Inflammatory Agents, Non-Steroidal; Cladribine; Clinical Trials as Topic; Dimethyl Fumarate; Fingolimod Hydrochloride; Fumarates; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Immunosuppressive Agents; Interferon beta-1b; Interferon-beta; Isoxazoles; Leflunomide; Minocycline; Multiple Sclerosis; Mycophenolic Acid; Propylene Glycols; Pyridones; Quinolones; Sphingosine | 2007 |
Compared benefit of approved and experimental immunosuppressive therapeutic approaches in multiple sclerosis.
Topics: Antibodies, Monoclonal; Cladribine; Cyclophosphamide; Drug Delivery Systems; Fingolimod Hydrochloride; Humans; Immunosuppressive Agents; Isoxazoles; Ligands; Mitoxantrone; Multiple Sclerosis; Propylene Glycols; Sphingosine | 2007 |
Emerging oral drugs for multiple sclerosis.
Topics: Administration, Oral; Cladribine; Crotonates; Fingolimod Hydrochloride; Fumarates; Humans; Hydroxybutyrates; Immunosuppressive Agents; Multiple Sclerosis; Nitriles; Propylene Glycols; Quinolones; Sphingosine; Toluidines | 2008 |
New oral drugs for multiple sclerosis.
Topics: Cladribine; Clinical Trials, Phase III as Topic; Crotonates; Fingolimod Hydrochloride; Fumarates; Humans; Hydroxybutyrates; Immunosuppressive Agents; Multiple Sclerosis; Nitriles; Propylene Glycols; Quinolones; Sphingosine; Toluidines | 2009 |
[Development of oral therapies for multiple sclerosis--fingolimod, cladribine and other drugs].
Topics: Cladribine; Clinical Trials as Topic; Fingolimod Hydrochloride; Humans; Immunosuppressive Agents; Multiple Sclerosis; Propylene Glycols; Sphingosine | 2010 |
Emerging therapies in relapsing-remitting multiple sclerosis.
Topics: Adjuvants, Immunologic; Administration, Oral; Alemtuzumab; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antibodies, Neoplasm; Antineoplastic Agents; Cladribine; Disease Progression; Fingolimod Hydrochloride; Humans; Immunosuppressive Agents; Multiple Sclerosis, Relapsing-Remitting; Propylene Glycols; Sphingosine; Treatment Outcome | 2010 |
Identification of targets and new developments in the treatment of multiple sclerosis--focus on cladribine.
Topics: Administration, Oral; Animals; Cladribine; Clinical Trials as Topic; Drug Delivery Systems; Drug Design; Fingolimod Hydrochloride; Humans; Immunosuppressive Agents; Multiple Sclerosis, Relapsing-Remitting; Propylene Glycols; Sphingosine | 2010 |
Multiple sclerosis therapies: molecular mechanisms and future.
Topics: Alemtuzumab; Animals; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antibodies, Monoclonal, Murine-Derived; Antibodies, Neoplasm; Cladribine; Crotonates; Daclizumab; Dimethyl Fumarate; Encephalomyelitis, Autoimmune, Experimental; Fingolimod Hydrochloride; Fumarates; Humans; Hydroxybutyrates; Immunoglobulin G; Immunosuppressive Agents; Immunotherapy; Mice; Multiple Sclerosis; Myelin Basic Protein; Nitriles; Peptide Fragments; Propylene Glycols; Quinolones; Rituximab; Sphingosine; Toluidines; Vaccines, DNA | 2010 |
Emerging oral agents for multiple sclerosis.
Topics: 4-Aminopyridine; Cladribine; Clinical Trials as Topic; Fingolimod Hydrochloride; Humans; Immunosuppressive Agents; Multiple Sclerosis; Propylene Glycols; Quinolones; Sphingosine | 2010 |
Oral therapies for multiple sclerosis: a review of agents in phase III development or recently approved.
Topics: Administration, Oral; Cladribine; Clinical Trials, Phase III as Topic; Crotonates; Dimethyl Fumarate; Fingolimod Hydrochloride; Fumarates; Humans; Hydroxybutyrates; Multiple Sclerosis; Nitriles; Propylene Glycols; Quinolones; Sphingosine; Toluidines | 2011 |
Magnetic resonance imaging as surrogate for clinical endpoints in multiple sclerosis: data on novel oral drugs.
Topics: Administration, Oral; Brain; Cladribine; Disability Evaluation; Disease Progression; Fingolimod Hydrochloride; Humans; Immunosuppressive Agents; Magnetic Resonance Imaging; Multiple Sclerosis; Predictive Value of Tests; Propylene Glycols; Recurrence; Regression Analysis; Reproducibility of Results; Sphingosine; Time Factors; Treatment Outcome | 2011 |
Therapeutic approach to multiple sclerosis by novel oral drug.
Topics: Administration, Oral; Cladribine; Crotonates; Diterpenes; Epoxy Compounds; Fingolimod Hydrochloride; Fumarates; Humans; Hydroxybutyrates; Multiple Sclerosis; Nitriles; Patents as Topic; Phenanthrenes; Propylene Glycols; Quinolones; Sphingosine; Toluidines | 2011 |
Multiple sclerosis in 2010: Advances in monitoring and treatment of multiple sclerosis.
Topics: Biomarkers; Cladribine; Fingolimod Hydrochloride; Humans; Immunosuppressive Agents; Magnetic Resonance Imaging; Multiple Sclerosis; Propylene Glycols; Randomized Controlled Trials as Topic; Sphingosine | 2011 |
Managing MS in a changing treatment landscape.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Cladribine; Fingolimod Hydrochloride; Humans; Immunosuppressive Agents; Interferon-beta; Mitoxantrone; Multiple Sclerosis; Natalizumab; Propylene Glycols; Sphingosine | 2011 |
[Current treatment of multiple sclerosis].
Topics: Administration, Oral; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Cladribine; Dimethyl Fumarate; Drug Administration Schedule; Fingolimod Hydrochloride; Fumarates; Glatiramer Acetate; Humans; Immunosuppressive Agents; Interferon-beta; Multiple Sclerosis; Multiple Sclerosis, Relapsing-Remitting; Natalizumab; Peptides; Propylene Glycols; Quinolones; Sphingosine; Treatment Outcome | 2011 |
Oral treatment for multiple sclerosis.
Topics: Administration, Oral; Cladribine; Clinical Trials as Topic; Crotonates; Dimethyl Fumarate; Fingolimod Hydrochloride; Fumarates; Humans; Hydroxybutyrates; Immunosuppressive Agents; Multiple Sclerosis, Relapsing-Remitting; Nitriles; Propylene Glycols; Quinolones; Sphingosine; Toluidines | 2011 |
[Emerging therapies for multiple sclerosis].
Topics: 4-Aminopyridine; Administration, Oral; Adult; Alemtuzumab; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antibodies, Monoclonal, Murine-Derived; Cladribine; Clinical Trials as Topic; Crotonates; Daclizumab; Dimethyl Fumarate; Fingolimod Hydrochloride; Fumarates; Humans; Hydroxybutyrates; Immunoglobulin G; Immunosuppressive Agents; Middle Aged; Multicenter Studies as Topic; Multiple Sclerosis; Nitriles; Propylene Glycols; Quinolones; Rituximab; Sphingosine; Toluidines; Young Adult | 2013 |
Synthesis of novel therapeutic agents for the treatment of multiple sclerosis: a brief overview.
Topics: Cladribine; Crotonates; Fingolimod Hydrochloride; Humans; Hydroxybutyrates; Molecular Structure; Multiple Sclerosis; Nitriles; Propylene Glycols; Quinolones; Small Molecule Libraries; Sphingosine; Toluidines | 2013 |
10 other study(ies) available for cladribine and sphingosine
| Article | Year |
|---|---|
The future of multiple sclerosis therapy.
Topics: Administration, Oral; Alemtuzumab; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antibodies, Neoplasm; Cladribine; Crotonates; Fingolimod Hydrochloride; Fumarates; Humans; Hydroxybutyrates; Immunologic Factors; Injections, Intravenous; Injections, Subcutaneous; Interferon-beta; Multiple Sclerosis; Nitriles; Propylene Glycols; Quinolones; Sphingosine; Toluidines | 2009 |
[Multiple sclerosis, the therapeutic arsenal of today and tomorrow].
Topics: Alemtuzumab; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antibodies, Neoplasm; Causality; Cladribine; Disabled Persons; Fingolimod Hydrochloride; Forecasting; France; Humans; Immunologic Factors; Immunosuppressive Agents; Multiple Sclerosis; Propylene Glycols; Research; Sphingosine; Vaccination; Vaccines, DNA | 2009 |
Oral therapy for multiple sclerosis--sea change or incremental step?
Topics: Administration, Oral; Arrhythmias, Cardiac; Cladribine; Disease Progression; Female; Fingolimod Hydrochloride; Herpesviridae Infections; Humans; Immunosuppressive Agents; Interferon beta-1a; Interferon-beta; Male; Multiple Sclerosis, Relapsing-Remitting; Propylene Glycols; Sphingosine | 2010 |
New drugs may improve, complicate treatment for multiple sclerosis.
Topics: Cladribine; Fingolimod Hydrochloride; Humans; Immunosuppressive Agents; Multiple Sclerosis; Propylene Glycols; Sphingosine | 2010 |
[Progress of therapy in patients with multiple sclerosis].
Topics: 4-Aminopyridine; Adrenal Cortex Hormones; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antibodies, Monoclonal, Murine-Derived; Brain; Cladribine; Clinical Trials as Topic; Fingolimod Hydrochloride; Magnetic Resonance Imaging; Multiple Sclerosis, Chronic Progressive; Multiple Sclerosis, Relapsing-Remitting; Natalizumab; Propylene Glycols; Rituximab; Sphingosine | 2010 |
Oral cladribine and fingolimod for relapsing multiple sclerosis.
Topics: Cladribine; Ethics, Research; Fingolimod Hydrochloride; Humans; Immunosuppressive Agents; Informed Consent; Multiple Sclerosis, Relapsing-Remitting; Placebos; Propylene Glycols; Research Design; Sphingosine | 2010 |
[Emerging treatments for multiple sclerosis].
Topics: Cladribine; Fingolimod Hydrochloride; Humans; Immunosuppressive Agents; Multiple Sclerosis; Prognosis; Propylene Glycols; Sphingosine | 2010 |
Update on emerging therapies for multiple sclerosis.
Topics: Cladribine; Fingolimod Hydrochloride; Humans; Immunosuppressive Agents; Mesenchymal Stem Cell Transplantation; Mesenchymal Stem Cells; Multiple Sclerosis; Neurology; Propylene Glycols; Sphingosine; Treatment Outcome | 2010 |
Multiple sclerosis: Cladribine--a contentious therapeutic contender for MS.
Topics: Cladribine; Clinical Trials as Topic; Device Approval; Fingolimod Hydrochloride; Humans; Immunosuppressive Agents; Multiple Sclerosis; Multiple Sclerosis, Relapsing-Remitting; Propylene Glycols; Sphingosine | 2011 |
Drugs: An injection of hope.
Topics: Alemtuzumab; Animals; Antibodies, Monoclonal, Humanized; Cladribine; Clinical Trials, Phase III as Topic; Crotonates; Dimethyl Fumarate; Disease Progression; Drug-Related Side Effects and Adverse Reactions; Fingolimod Hydrochloride; Fumarates; Humans; Hydroxybutyrates; Inflammation; Multiple Sclerosis; Natalizumab; Nitriles; Propylene Glycols; Quinolones; Risk Assessment; Sphingosine; Toluidines; United States; United States Food and Drug Administration | 2012 |